TY - JOUR
T1 - Immunohistochemical expression pattern of RIP5, FGFR1, FGFR2 and HIP2 in the normal human kidney development
AU - Racetin, Anita
AU - Raguž, Fila
AU - Durdov, Merica Glavina
AU - Kunac, Nenad
AU - Saraga, Marijan
AU - Sanna-Cherchi, Simone
AU - Šoljić, Violeta
AU - Martinović, Vlatka
AU - Petričević, Joško
AU - Kostić, Sandra
AU - Mardešić, Snježana
AU - Tomaš, Sandra Zekić
AU - Kablar, Boris
AU - Restović, Ivana
AU - Lozić, Mirela
AU - Filipović, Natalija
AU - Saraga-Babić, Mirna
AU - Vukojević, Katarina
N1 - Funding Information:
This work was supported by the Croatian Science Foundation (grant no. IP-06-2016-2575 ); splitsko-dalmatinska županija 2017 . “Capacity building for research development and kidney disease diagnosis“.
Publisher Copyright:
© 2019 Elsevier GmbH
PY - 2019/7
Y1 - 2019/7
N2 - Aim: Present study analyses the co-localisation of RIP5 with FGFR1, FGFR2 and HIP2 in the developing kidney, as RIP5 is a major determinant of urinary tract development, downstream of FGF-signaling. Methods: Paraffin embedded human kidney tissues of 16 conceptuses between the 6th-22th developmental week were analysed using double-immunofluorescence method with RIP5/FGFR1/FGFR2 and HIP2 markers. Quantification of positive cells were performed using Kruskal–Wallis test. Results: In the 6th week of kidney development RIP5 (89.6%) and HIP2 (39.6%) are strongly expressed in the metanephric mesenchyme. FGFR1 shows moderate/strong expression in the developing nephrons (87.3%) and collecting ducts (70.5%) (p < 0.05). RIP5/FGFR1 co-localized at the marginal zone and the ureteric bud with predominant FGFR1 expression. FGFR2 (26.1%) shows similar expression pattern as FGFR1 (70.5%) in the same kidney structures. RIP5/FGFR2 co-localized at the marginal zone and the collecting ducts (predominant expression of FGFR2). HIP2 is strongly expressed in collecting ducts (96.7%), and co-localized with RIP5. In 10th week, RIP5 expression decrease (74.2%), while the pattern of expression of RIP5 and FGFR1 in collecting ducts (33.4% and 91.9%) and developing nephrons (21.9% and 32.4%) (p < 0.05) is similar to that in the 6th developmental week. Ureter is moderately expressing RIP5 while FGFR1 is strongly expressed in the ureteric wall. FGFR2 is strongly expressed in the collecting ducts (84.3%) and ureter. HIP2 have 81.1% positive cells in the collecting duct. RIP5/FGFR1 co-localize in collecting ducts and Henley's loop. Conclusions: The expression pattern of RIP5, FGFR1, FGFR2 and HIP2 in the human kidney development might indicate their important roles in metanephric development and ureteric muscle layer differentiation through FGF signaling pathways.
AB - Aim: Present study analyses the co-localisation of RIP5 with FGFR1, FGFR2 and HIP2 in the developing kidney, as RIP5 is a major determinant of urinary tract development, downstream of FGF-signaling. Methods: Paraffin embedded human kidney tissues of 16 conceptuses between the 6th-22th developmental week were analysed using double-immunofluorescence method with RIP5/FGFR1/FGFR2 and HIP2 markers. Quantification of positive cells were performed using Kruskal–Wallis test. Results: In the 6th week of kidney development RIP5 (89.6%) and HIP2 (39.6%) are strongly expressed in the metanephric mesenchyme. FGFR1 shows moderate/strong expression in the developing nephrons (87.3%) and collecting ducts (70.5%) (p < 0.05). RIP5/FGFR1 co-localized at the marginal zone and the ureteric bud with predominant FGFR1 expression. FGFR2 (26.1%) shows similar expression pattern as FGFR1 (70.5%) in the same kidney structures. RIP5/FGFR2 co-localized at the marginal zone and the collecting ducts (predominant expression of FGFR2). HIP2 is strongly expressed in collecting ducts (96.7%), and co-localized with RIP5. In 10th week, RIP5 expression decrease (74.2%), while the pattern of expression of RIP5 and FGFR1 in collecting ducts (33.4% and 91.9%) and developing nephrons (21.9% and 32.4%) (p < 0.05) is similar to that in the 6th developmental week. Ureter is moderately expressing RIP5 while FGFR1 is strongly expressed in the ureteric wall. FGFR2 is strongly expressed in the collecting ducts (84.3%) and ureter. HIP2 have 81.1% positive cells in the collecting duct. RIP5/FGFR1 co-localize in collecting ducts and Henley's loop. Conclusions: The expression pattern of RIP5, FGFR1, FGFR2 and HIP2 in the human kidney development might indicate their important roles in metanephric development and ureteric muscle layer differentiation through FGF signaling pathways.
UR - http://www.scopus.com/inward/record.url?scp=85064825726&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064825726&partnerID=8YFLogxK
U2 - 10.1016/j.acthis.2019.04.011
DO - 10.1016/j.acthis.2019.04.011
M3 - Article
C2 - 31047684
AN - SCOPUS:85064825726
SN - 0065-1281
VL - 121
SP - 531
EP - 538
JO - Acta Histochemica
JF - Acta Histochemica
IS - 5
ER -